Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) has entered a landmark licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), the global leader in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics, to jointly develop six innovative siRNA therapies leveraging Ribo’s proprietary liver-targeting RiboGalSTAR platform. The deal, valued at up to USD 4.4 billion, represents one of the largest RNA therapeutic partnerships in the rapidly expanding MASH market.
Transaction Structure
Element
Detail
Licensor
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938)
Licensee
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
Technology Platform
RiboGalSTAR – Liver-targeting siRNA delivery system
Assets
Six preclinical siRNA therapies (single-target and dual-target)
Technology transfer; lead candidate selection from 6-asset portfolio
2026
Preclinical
IND-enabling studies; GLP toxicology
2026-2027
Clinical
Phase I/II MASH trials (combination with resmetirom potential)
2027-2028
Regulatory
NDA submissions; global commercialization
2029+
Royalties
Revenue participation based on Madrigal global sales
Commercial launch
Forward‑Looking Statements This brief contains forward‑looking statements regarding Ribo Life Science siRNA clinical development, Madrigal Pharmaceuticals’ MASH market expansion, and RiboGalSTAR platform validation in liver diseases. Actual results may differ due to siRNA delivery efficiency challenges, combination therapy safety profiles, and competitive dynamics with Arrowhead and Alnylam in MASH.-Fineline Info & Tech
By Fineline Cube